Kivu Bioscience–Novo Group: investment, 202410 financing round Series A totalling $92m incl lead investor Novo Holdings |
2024-10-28 |
Kivu Bioscience–Odlander Fredrikson: investment, 202410 financing round Series A totalling $92m incl new + co-investor HealthCap |
2024-10-28 |
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings |
2024-10-28 |
Booster Therapeutics–Novo Group: investment, 202410 seed financing round totalling $15m incl co-lead investor Novo Holdings |
2024-10-10 |
Booster Therapeutics–SEVERAL: investment, 202410 seed financing round $15m led by Apollo Health Ventures + Novo Holdings |
2024-10-10 |
Novo Group–Evotec: cell therapy manufacturing, 202409– collab technology development €na RnD funding + upfront + milestone payments plus royalties |
2024-09-26 |
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries |
2024-09-16 |
PanTera–SEVERAL: investment, 202409 financing round Series A €93m led by EQT Life Sciences |
2024-09-11 |
Biomatter Designs–Inventure: investment, 202408 seed financing round totalling €6.5m co-led by Inventure |
2024-08-05 |
Biomatter Designs–SEVERAL: investment, 202408 seed financing round €6.5m led by Inventure + UVC Partners |
2024-08-05 |
Draupnir Bio–ABP (NL): Investment, 202407 seed financing round totalling €12m incl existing investor Inkef Capital |
2024-07-17 |
Draupnir Bio–Denmark (govt): Investment, 202407 seed financing round totalling €12m incl new investor EIFO |
2024-07-17 |
Draupnir Bio–Gilde Investment: Investment, 202407 seed financing round totalling €12m incl existing investor Gilde Healthcare Partners |
2024-07-17 |
Draupnir Bio–Mitsubishi Chemical: Investment, 202407 seed financing round totalling €12m incl new investor MP Healthcare |
2024-07-17 |
Draupnir Bio–Novo Group: Investment, 202407 seed financing round totalling €12m incl existing investor Novo Holdings |
2024-07-17 |
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings |
2024-07-17 |
Asceneuron–EQT: investment, 202407 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences - LSP Dementia Fund |
2024-07-16 |
Asceneuron–Novo Group: investment, 202407 financing round Series C totalling $100m incl lead investor Novo Holdings |
2024-07-16 |
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings |
2024-07-16 |
HepaRegenix–Novo Group: investment, 202407 financing round Series C totalling €15m incl existing + co-investor Novo Holdings |
2024-07-10 |
HepaRegenix–SEVERAL: investment, 202407 financing round Series C €15m led by Vesalius Biocapital IV |
2024-07-10 |
SciRhom–Hadean Ventures: investment, 202407 financing round Series A totalling €63m incl co-lead investor Hadean Ventures |
2024-07-09 |
SciRhom–SEVERAL: investment, 202407 financing round Series A €63m |
2024-07-09 |
Myricx Pharma–Novo Group: investment, 202407 financing round Seires A totalling £90m incl new + co-lead investor Novo Holidngs |
2024-07-08 |
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth |
2024-07-08 |
Sequrna–Genovis: investment, 202407 acquisition of 25% shareholding €na by Genovis with conditional call option until 6/27 to acquire all shares |
2024-07-04 |
Forbion–SEVERAL: investment, 202406 first closing €75m of Forbion BioEconomy Fund I incl KfW Capital + Novo Holdings + Rentenbank |
2024-06-20 |
PINK gegen Brustkrebs–Sidekick Health: investment, 202406 acquisition of PINK! by Sidekick Health |
2024-06-18 |
Novo Group–Hikma: investment, 202406– acquisition $135m upfront + $50m milestones part of Xellia’s business incl Cleveland plant + Zabreg RnD Center |
2024-06-17 |
Moleculent–ARCH Venture: investment, 2020406 financing round Series A totalling $26m incl lead investor ARCH Venture Partners |
2024-06-11 |
Moleculent–Bioscribe: public relations, 202406 service existent by Bioscribe |
2024-06-11 |
Moleculent–Eir Ventures: investment, 2020406 financing round Series A totalling $26m incl co-lead investor Eir Ventures |
2024-06-11 |
Moleculent–OTHER: investment, 2020406 financing round Series A totalling $26m incl existing investors as co-investors |
2024-06-11 |
Moleculent–SEVERAL: investment, 2020406 financing round Series A $26m led by ARCH Venture Partners |
2024-06-11 |
Adcendo–Gilde Investment: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Gilde Healthcare |
2024-05-29 |
Adcendo–KKR: investment, 202405 financing round Series A 2nd extension totalling €16m incl new + lead investor Dawn Biopharma |
2024-05-29 |
Adcendo–Novo Group: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Novo Holdings |
2024-05-29 |
Adcendo–Odlander Fredrikson: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor HealthCap |
2024-05-29 |
Adcendo–Pontifax: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Pontifax Venture Capital |
2024-05-29 |
Adcendo–RA Capital: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor RA Capital Management |
2024-05-29 |
Adcendo–SEVERAL: investment, 202405 financing round Series A 2nd extension €16m bringing total Series A to €96m |
2024-05-29 |
Adcendo–Ysios Capital: investment, 202405 financing round Series A 2nd extension totalling €16m incl existing + co-investor Ysios Capital |
2024-05-29 |
Calliditas Therapeutics–Asahi Kasei: investment, 202405– acquisition cash tender offer SEK11.8b (JPY174b) by Asahi Kasei ANNOUNCED |
2024-05-28 |
Single Use Support–Novo Group: investment, 202405 acquisition of 60% majority share by Novo Holdings |
2024-05-15 |
ArgusEye–Eir Ventures: investment, 202405 financing round totalling €2.8m incl existing + co-lead investor Eir Ventures |
2024-05-13 |
ArgusEye–SEVERAL: investment, 202405 financing round €2.8m led by Voima Ventures + co-led by Eir Ventures |
2024-05-13 |
ArgusEye–Voima Ventures: investment, 202405 financing round totalling €2.8m incl lead investor Voima Ventures |
2024-05-13 |
Bluejay Therapeutics–SEVERAL: investment, 202405 financing round Series C $182m co-led by Frazier LS + undisclosed institutional LS investor |
2024-05-09 |
Commit Biologics–Bioqube Ventures: investment, 202405 seed financing round totalling €16m incl co-lead investor Bioqube Ventures |
2024-05-09 |
Commit Biologics–Novo Group: investment, 202405 seed financing round totalling €16m incl co-lead investor Novo Holdings |
2024-05-09 |
Commit Biologics–SEVERAL: investment, 202405 seed financing round €16m led by Bioqube Ventures + Novo Holdings |
2024-05-09 |
Insempra–EQT: investment, 202405 financing round Series A totalling $20m incl existing investor EQT Ventures |
2024-05-07 |
Insempra–SEVERAL: investment, 202405 financing round Series A $20m with existing + new investors |
2024-05-07 |
Theolytics–SEVERAL: investment, 202404 financing round £19m incl new investor Sound Bioventures |
2024-04-17 |
Theolytics–Sound Bioventures: investment, 202404 financing round totalling £19m incl new investor Sound Bioventures |
2024-04-17 |
ProfoundBio–Genmab: investment, 202403– acqusition $1.8b in cash of ProfoundBio by Genmab ANNOUNCED |
2024-04-03 |
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases |
2024-03-26 |
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED |
2024-03-25 |
Amolyt Pharma–AstraZeneca: investment, 202403– acquisition $800m upfront cash + $250m milestones |
2024-03-14 |
Asgard Therapeutics–Boehringer: investment, 202403 financing round Series A totalling €30m incl existing + co-investor BIVF |
2024-03-14 |
Asgard Therapeutics–JnJ: investment, 202403 financing round Series A totalling €30m incl co-lead investor JnJ Innovation JJDC |
2024-03-14 |
Asgard Therapeutics–Novo Group: investment, 202403 financing round Series A totalling €30m incl existing + co-investor Novo Holdings |
2024-03-14 |
Asgard Therapeutics–SEVERAL: investment, 202403 financing round Series A €30m co-led by RV Invest + JnJ Innovation |
2024-03-14 |
Asgard Therapeutics–Sweden (govt): investment, 202403 financing round Series A totalling €30m incl existing + co-investor Industrifonden |
2024-03-14 |
Asgard Therapeutics–Vetter: investment, 202403 financing round Series A totalling €30m incl co-lead investor RV Invest |
2024-03-14 |
Tubulis–EQT: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor EQT Life Sciences |
2024-03-14 |
Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest |
2024-03-14 |
Commit Biologics–Denmark (govt): grant, 202402 Innobooster Grant DKK5m from Innovation Fund Denmark |
2024-02-14 |
TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces |
2024-01-30 |
Vico Therapeutics–EQT: investment, 202401 financing round Series B totalling €54m incl existing + co-lead investor EQT Life Sciences |
2024-01-05 |
Vico Therapeutics–SEVERAL: investment, 202401 financing round Series B €54m led by new investor Ackermans & van Haaren |
2024-01-05 |
Resalis Therapeutics–Claris Ventures: investment, 202401 financing round Series A totalling €10m incl existing + co-investor Claris Ventures |
2024-01-04 |
Resalis Therapeutics–OTHER: investment, 202401 financing round Series A totalling €10m incl angel investos as existing + co-investors |
2024-01-04 |
Resalis Therapeutics–SEVERAL: investment, 202401 financing round Series A €10m led by new investor Sunstone Life Science Ventures |
2024-01-04 |
Resalis Therapeutics–Sunstone Life Science: investment, 202401 financing round Series A totalling €10m incl new + lead investor Sunstone LSV |
2024-01-04 |
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ |
2023-12-21 |
Freya Biosciences–Angelini: investment, 202312 financing round Series A totalling $38m incl co-investor Angelini Ventures |
2023-12-12 |
Freya Biosciences–Corundum Systems Biology: investment, 202312 financing round Series A totalling $38m incl co-investor Corundum Systems Biology |
2023-12-12 |
Freya Biosciences–Crescent Enterprises: investment, 202312 financing round Series A totalling $38m incl co-investor CE-Ventures |
2023-12-12 |
Freya Biosciences–Denmark (govt): investment, 202312 financing round Series A totalling $38m incl co-investor EIFO |
2023-12-12 |
Freya Biosciences–Indaco Venture: investment, 202312 financing round Series A totalling $38m incl co-investor Indaco Venture Partners |
2023-12-12 |
Freya Biosciences–OMX Ventures: investment, 202312 financing round Series A totalling $38m incl co-lead investor OMX Ventures |
2023-12-12 |
Freya Biosciences–PERSON: investment, 202312 financing round Series A totalling $38m incl co-investor Mike Jafar Family Office |
2023-12-12 |
Freya Biosciences–SEVERAL: investment, 202312 financing round Series A $38m led by Sofinnova Partners + OMX Ventures |
2023-12-12 |
Freya Biosciences–Sofinnova: investment, 202312 financing round Series A totalling $38m incl co-lead investor Sofinnova Partners |
2023-12-12 |
Shinobi Therapeutics–EQT: investment, 202312 financing round Series A totalling $51m incl co-lead investor EQT Life Sciences |
2023-12-12 |
Shinobi Therapeutics–SEVERAL: investment, 202312 financing round Series A $51m led by EQT LS + F-Prime Capital + Eight Roads Ventures Japan |
2023-12-12 |
Oblique Therapeutics–AAX Biotech: antibody development, 202311– collab developm of antibodies for pain using Seqitope to characterise candidates |
2023-11-28 |
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital |
2023-11-15 |
Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences |
2023-11-14 |
VectorY–EQT: investment, 202311 financing round Series A totalling €129m incl new + co-lead investor EQT Life Sciences Dementia Fund |
2023-11-13 |
VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund |
2023-11-13 |
AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004 |
2023-11-09 |
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion |
2023-11-07 |
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures |
2023-11-07 |
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC |
2023-11-01 |
AstraZeneca–Nanoform: drug delivery technology, 202310– license ww to Starmap Online |
2023-10-23 |
FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater |
2023-10-23 |
FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater |
2023-10-23 |
Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher |
2023-10-17 |